Skip to content
Open access

Long-term outcomes of high-dose hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer.

Sep 2026 · Journal of Radiation Research · 0 citations
Medicine

TL;DR

High-dose hyperfractionated radiotherapy may be a feasible dose-escalated option for patients with LS-SCLC, with acceptable toxicity, with published data on the long-term outcomes of this specific regimen.

Abstract

Concurrent chemoradiotherapy with thoracic radiotherapy of 45 Gy in 30 twice-daily fractions is the standard treatment for limited-stage small-cell lung cancer (LS-SCLC). However, the optimal thoracic radiotherapy dose remains uncertain. This study aimed to evaluate the efficacy and safety of high-dose hyperfractionated radiotherapy for LS-SCLC. We retrospectively analyzed 38 patients with LS-SCLC who received high-dose hyperfractionated radiotherapy at multiple institutions in Yamagata Prefecture between 2008 and 2012. Radiotherapy was delivered at a total dose of 60 Gy in 50 twice-daily fractions of 1.2 Gy. The median follow-up was 31 months for the entire cohort and 107 months for surviving patients. The 3- and 5-year overall survival and progression-free survival were 46.1 and 26.2%, and 36.9 and 26.9%, respectively. The cumulative incidence of local recurrence in the high-dose region at 3- and 5-years was 13.5 and 18.9%, respectively. Grade 3 radiation pneumonitis occurred in three patients (7.9%). No grade 4 or higher radiation pneumonitis or grade 3 or higher esophagitis was observed. Grade 4 cytopenia occurred in six patients (16%). High-dose hyperfractionated radiotherapy may be a feasible dose-escalated option for patients with LS-SCLC, with acceptable toxicity. Published data on the long-term outcomes of this specific regimen are limited.

Read PDF

Similar papers

Review Oct 2026

Safety and early outcomes of external beam radiation therapy with low dose brachytherapy boost in patients with prostate cancer: A single institution experience.

Findings support this approach for appropriately selected patients in routine clinical care for intermediate- and high-risk prostate cancer, as contemporary real-world evidence remains limited.

Z. El Kouzi, M. Rooney, Adam B. Samman et al. · 0 citations
Open access Oct 2026

Efficacy and Safety of Low-Dose Hypofractionated Radiotherapy Combined with Immunotherapy for Liver Metastases: A Single-Center Retrospective Analysis

Objective To evaluate the efficacy and safety of low-dose hypofractionated radiotherapy (LDHRT) for liver metastases when combined with immunotherapy. Methods Patients with liver metastases receiving immunotherapy were enrolled in this study at Changzhou Second People’s Hospital from January 2019 to May 2025 (Ethics Ap...

Lan-Qun Qin, Yan-Shuang Wei, Li Tao et al. · 0 citations
Sep 2026

High-dose-rate brachytherapy boost with external beam radiotherapy for localized prostate cancer: Long-term outcomes and toxicity in 607 predominantly high-risk patients.

OBJECTIVE To report long-term outcomes and late toxicity after external beam radiotherapy (EBRT) with single-fraction high-dose-rate brachytherapy boost (HDR-BTB) for localized prostate cancer, examining HDR-BT sequencing and risk stratification. METHODS AND MATERIALS We retrospectively analyzed 607 (2012-2023) men t...

M. Choudhury, F. Adeoye, S. Nageshwaran et al. · 0 citations
Open access Sep 2026

Image-guided high-dose-rate brachytherapy after short-course external beam radiotherapy for elderly/frail rectal cancer patients.

HDR-BT dose escalation after initial EBRT represents a feasible non-operative treatment option for patients unfit for surgery with promising long-term local control and the incidence of late grade 3 rectal bleeding requires careful patient selection.

Alexander Kristen, N. Tselis, M. Diefenhardt et al. · 0 citations
Open access Sep 2026

Long-term outcome after partial breast irradiation with interstitial multi-catheter high-dose-rate brachytherapy: Results from a Phase II prospective study with extended follow-up.

PBI using interstitial multi-catheter high dose-rate brachytherapy is effective and well-tolerated for selected early-stage breast cancer showing excellent long-term toxicity, cosmetic profiles, and outcomes.

Valeria Epifani, P. Anselmo, F. Arcidiacono et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.